TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Accessible volume and quality of tumor tissue for vaccine production~* MRI after surgery with minimal tumor remnant.~* Between 18 and 70 years of age.~* Must have histologically confirmed glioma grade IV, and a candidate for combined radiation therapy and chemotherapy (Stupps regimen).~* Must be ambulatory with a ECOG performance status 0 or 1.~* A minimum 4 weeks must have elapsed between the end of glucocorticoid treatment and beginning of vaccination.~* Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented.~Exclusion Criteria:~* Tumor in a localization where a modest increase in size due to reactive oedema may have a large impact on patients neurological condition.~* Large tumor remnant after surgery.~* History of prior malignancy other than glioma, with the exception of curatively treated basal cell or squamous cell carcinoma of the skin and ca. cervicis stage IB.~* Chronic active infection requiring antibiotic therapy.~* Significant cardiac or other medical illness that would limit activity or survival, such as severe congestive heart failure, unstable angina, or serious cardiac arrhythmia.~* Prior splenectomy.~* Glucocorticoid treatment not possible to terminate due to autoimmune disease or increased intracranial pressure.~* Adverse reactions to vaccines such as asthma, anaphylaxis or other serious reactions.~* History of immunodeficiency or autoimmune disease such as rheumatoid arthritis, systemic lupus erythematosus, scleroderma, polymyositis- dermatomyositis, juvenile onset insulin dependent diabetes, or a vasculitic syndrome.~* Chemotherapy or other potentially immune-suppressive therapy that has been administered within 4 weeks prior to vaccination.~* Pregnancy or lactation.~* Any reason why, in the opinion of the investigator, the patient should not participate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy Safety and Tolerability of Nitric Oxide Given Intermittently Via Inhalation to Subjects With Bronchiolitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 1. Pediatric subjects 0-12-months old.~   a. Including subjects born at ≥28 weeks of gestation.~2. Subjects with acute bronchiolitis requiring in-patient hospitalization expected for 24 hours and more.~3. Clinical score of between 7 to 10 at Screening (without oxygen supplementation).~4. Parent/guardian who is willing and able to sign, an informed consent on behalf of the subject.~Exclusion Criteria:~1. 1. Subjects diagnosed with alveolar pneumonia on Chest X-ray (including WBC≥ 15,000/ul, and Temp \>39°C).~2. Previous diagnosis of asthma or requirement for asthma medications.~3. Subjects with \>2 previous wheezing episodes.~4. History of life-threatening respiratory distress that requires admission to an intensive care unit for treatment.~5. Subjects with history of methemoglobinemia and/or methemoglobin \>5% for any cause.~6. Use of an investigational drug within 30 days before enrolment and/or expected to participate in a new study within 90 days.~7. History of frequent epistaxis (\>1 episode/month) or significant hemoptysis within 30 days prior to enrolment (≥5 mL of blood in one coughing episode or \>30 mL of blood in a 24-hour period.~8. Taken medications such as chronic systemic corticosteroids, CNS stimulants, theophylline or aminophylline, anti-arrhythmic within a certain time period prior to the study.~9. Unable to comply with the study procedures.~10. Underlying genetic disorders (including Cystic fibrosis) or hypotonia.~11. Having the following signs or symptoms: 1) known pulmonary (lung) and/or cardiac (heart) congenital malformations 2) an underlying renal, or liver insufficiency, immunodeficiency, encephalopathy; 3) known or suspected foreign body aspiration.~12. Any reason that, in the opinion of the investigator, may make the subject unfit for this clinical trial.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 12 Months
- Healthy Volunteers: f

Study Arms:
- Group 1 - Nitric Oxide treatment (Type: EXPERIMENTAL): • Group 1 (NO treatment) - will receive inhalations of 160 ppm NO combined with O2/air for 30 minutes, every 3-4.5 hours, five times a day (24 hours), for up to 5 days (maximum 25 inhalations), in addition to standard supportive treatment.
- Group 2 - Control treatment (Type: ACTIVE_COMPARATOR): • Group 2 (Control) - will receive inhalations O2/air using the same treatment schedule and equipment as group 1, in addition to standard supportive treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged at least 18 years~* Patient with a diagnosis of stable moderate to severe chronic plaque psoriasis~* For whom the treating dermatologist has made the decision to initiate apremilast treatment in accordance with the local label and reimbursement criteria i.e. a history of failure or contra-indication or intolerance to other systemic therapy including ciclosporin, methotrexate, or phototherapy UVA + psoralen (PUVA therapy)~* Patient having started apremilast up to 4 weeks before the enrolment visit for treatment of moderate to severe chronic plaque psoriasis even if apremilast has been stopped before inclusion in the study~* Patient literate and willing to fill in questionnaires~* Non-opposition form signed by the investigator indicating that the patient received information about the study, and orally agreed.~Exclusion Criteria:~* Patient who refuses to participate in the study or is unable to give his/her oral consent~* Patient having participated in an interventional study in the last 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients treated with Apremilast (Type: None): Patients with moderate to severe chronic plaque psoriasis after failure or contra-indication or intolerance to other systemic therapy including ciclosporin, methotrexate, or phototherapy UVA + psoralen (PUVA therapy).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extension of Phase II Therapeutic Trial With a Humanized Non-Mitogenic CD3 (ChAgly CD3) Monoclonal Antibody in Recently Diagnosed Type 1 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with Type 1 diabetes mellitus included in the phase II therapeutic trial with a humanized non-mitogenic CD3 monoclonal antibody (ChAgly CD3) at time of clinical diagnosis and who agree and are likely to comply with the investigator's instructions~Exclusion Criteria:~* Any illness that, in the opinion of the investigator, might confound the results of the study or pose additional risks to the patient~* Use of illicit drugs or over consumption of alcohol (\> 3 beers/day)~* Being legally incapacitated, having significant emotional problems at the time of the study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- B (Type: PLACEBO_COMPARATOR): None
- A (Type: ACTIVE_COMPARATOR): ChAgly CD3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RAL-eve Study: Raltegravir Substitution Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry.~2. ART for at least 6 months prior to study entry with a regimen that includes enfuvirtide.~3. Self-defined infusion site reaction to enfuvirtide (usually will be painful inflammatory nodules)~4. No change in ART regimen for at least 3 months prior to study entry.~5. CD4+ cell count \>50/mm3 at screening (obtained within 60 days prior to study entry).~6. Documentation of HIV-1 RNA below the limit of quantification of an ultrasensitive assay~7. All HIV-1 RNA levels obtained within 6 months prior to study entry are below the limits of quantification on all tests, except as explained above in section 4.1.6 for a single detectable viral load of \<50 copies but \<200 copies in last 6 months.~8. Laboratory values obtained within 60 days prior to entry:~   * Absolute neutrophil count (ANC) \>750/mm3~  * Hemoglobin \>9.0 g/dL for female subjects and\>10.0 g/dL for male subjects~  * Platelet count \>50,000/mm3~  * Calculated creatinine clearance (CrCl) \>30 mL/min, as estimated by the Cockcroft-Gault equation\*~  * AST (SGOT), ALT (SGPT), and alkaline phosphatase \<5 x ULN~  * Total bilirubin \<2.5 x ULN. If the subject is taking an indinavir- or atazanavir-containing regimen at the time of screening, total bilirubin \<5 x ULN is acceptable.~9. For females of reproductive potential will need a negative serum or urine pregnancy test within 48 hours prior to entry.~10. Men and women age \>18 years.~11. Ability and willingness of subject to provide informed consent.~Exclusion Criteria:~1. Unstable clinical condition, such as unstable cardiac disease, or cancer requiring ongoing chemotherapy or radiation therapy, or other medical condition which, in the opinion of the investigator, would preclude a subject from safely undergoing study procedures.~2. Breast-feeding or pregnancy.~3. An opportunistic infection within 60 days prior to entry.~4. Known allergy/sensitivity or any hypersensitivity to components of study drug(s) or their formulation.~5. Active drug or alcohol use or dependence that, in the opinion of the Protocol Director, would interfere with adherence to study requirements.~6. Receipt of a non-HIV vaccination within 30 days prior to study entry or plan for receipt of vaccination during the study.~7. Plan to change the background ART within 24 weeks after study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Inflammatory Responses to Lipid Emulsions in Children Before and After Open Heart Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 36 weeks gestation~* 3 months corrected age~* appropriate for gestational age (AGA)~* admitted for surgical correction of congenital heart defects (single ventricle, tetralogy of Fallot, truncus and complex biventricular repairs)~* enteral nutrition at 30 kcal/kilogram/day~Exclusion Criteria:~* 5 minute Apgar score of 4~* major congenital defect other than heart defect~* presence of significant neonatal morbidity (intraventricular hemorrhage (IVH) grade 3 or greater, necrotizing enterocolitis (NEC) and surgical abdomen)~* any metabolic disorder~* any endocrine disorder~* medications which alter eicosanoid metabolism including indomethacin, acetylsalicylate (with exception of steroids which will be analyzed independently)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 3 Months
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
KEY INCLUSION CRITERIA:~1. Male or female, ages 18 to 75 years.~2. History of GERD symptoms for at least 3 months immediately before screening.~3. Heartburn for at least 2 days a week for at least 1 month before screening.~4. Esophageal erosions of Los Angeles (LA) grades C or D based on EGD taken within 14 days prior to enrollment.~5. Subjects who are H. pylori negative based on a screening test.~6. Females should be either of non-childbearing potential or of childbearing potential. Females of childbearing potential must have negative pregnancy tests prior to randomization. Female subjects of childbearing potential must agree to use medically acceptable methods of contraception.~7. Subjects must be able to read, write, and understand the language of the symptom diary.~KEY EXCLUSION CRITERIA:~1. Current or a history of esophageal motility disorders.~2. Current or a history of Barrett's esophagus. Current esophageal strictures or esophagitis (known or suspected to be due to etiology other than GERD such as infection or medications).~3. Current or a history of Zollinger-Ellison syndrome and other acid hypersecretory conditions, or current gastric or duodenal ulcer.~4. Current or a history of cancer, with the exception of fully excised skin basal cell carcinoma.~5. Inflammatory bowel disease.~6. Unstable diabetes mellitus.~7. History of esophageal, gastric and duodenal surgery except simple suturing of an ulcer.~8. Subjects who require daily use of nonsteroidal anti-inflammatory drugs (NSAIDs), oral steroids (-\>;= 20 mg/day prednisone or equivalent), or aspirin (-\>; 325 mg/day).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of Varenicline for 4-weeks Prior to Quitting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Smokers seeking treatment~* Aged 18 and over~* Consenting to take part in the trial~Exclusion Criteria:~* Pregnant or breastfeeding~* End-stage renal disease~* Used varenicline in the past 6 months~* Unable to fill in questionnaires in English~* Current psychiatric illness~* Current serious illness including uncontrolled hypertension and recent cardiac event~* Sensitivity to varenicline currently enrolled in other research projects.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Varenicline pre-treatmemt (Type: EXPERIMENTAL): Participants will use varenicline (1mg BD) 4-weeks prior to quitting
- Placebo (Type: PLACEBO_COMPARATOR): Participants will use 3 weeks of placebo, followed by 1 week of varenicline, prior to quitting

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rosuvastatin Effect on Serial Echocardiographic Measurement of Coronary Flow Velocity Reserve

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Controlled Hypertension: treated SBP \< 140 mmHg and DBP \< 90 mmHg~* LDL cholesterol \> 130 mg/dL~* Patients with statin-naive state, defined as receiving no statin therapy for more than 3 months during the previous 12 months~* Any 1 of these cardiovascular risk factors required: smoking, Type 2 DM, age over 55 (men) or 65 (women), peripheral vascular disease, history of cerebrovascular event, family history of early CHD before age 55, HDL cholesterol \< 40 mg/dL~Exclusion Criteria:~* A previous history of intolerance or hypersensitivity to statins~* Uncontrolled hypertension; SBP ≥ 140 mmHg or DBP ≥ 90 mmHg~* Previous MI or currently treated angina pectoris~* Stroke, Transient ischemic attack \< 3 months~* Secondary hypertension~* Fasting serum triglyceride \> 500 mg/dL~* Clinical congestive heart failure~* Uncontrolled arrhythmia~* Left ventricular hypertrophy: LV mass index \> 134g/m2 (male) or \>110g/m2 (female)~* Concomitant clinically important respiratory, hematological, gastrointestinal, hepatic, renal or other disease~* Pregnant or lactating women and those of child-bearing potential

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Rosuvastatin (Type: EXPERIMENTAL): Rosuvastatin 10mg qd for 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* lymphocyte predominant Hodgkin´s lymphoma (histologically proven)~* clinical stage IA (without risk factors: large mediastinal mass, extranodal involvement, ESR \> 50mm/h)~* age 18 - 75~* WHO performance status 0-3~* normal organ function~* written informed consent~Exclusion Criteria:~* classical Hodgkin´s lymphoma~* composite lymphoma~* leucocytes \< 3000/µl~* thrombocytes \< 100.000/µl

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed unifocal or multifocal supratentorial WHO grade II astrocytoma (diffuse fibrillary, protoplasmic, or gemistocytic), oligodendroglioma, or oligoastrocytoma~* Patients with neurofibromatosis are eligible~* No other low-grade histologies, including:~  * Pilocytic astrocytoma~ * Subependymal giant cell astrocytoma of tuberous sclerosis~ * Subependymoma~ * Pleomorphic xanthoastrocytoma~ * Presence of a neuronal element such as ganglioglioma~ * Dysneuroembryoplastic epithelial tumor~* No presence of any high-grade glioma, including:~  * Anaplastic astrocytoma~ * Glioblastoma multiforme~ * Anaplastic oligodendroglioma~ * Anaplastic oligoastrocytoma~* No tumors in nonsupratentorial or other locations including optic chiasm, optic nerve(s), pons, medulla, cerebellum, or spinal cord~* No evidence of spread to spinal meninges or noncontiguous cranial meninges (i.e., leptomeningeal gliomatosis)~* No gliomatosis cerebri~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Hematopoietic:~* For high-risk patients:~  * Granulocyte count at least 1,500/mm\^3~ * Platelet count normal~Hepatic:~* Bilirubin no greater than 2 times normal~* SGOT or SGPT no greater than 4 times normal~* Alkaline phosphatase no greater than 2 times normal~Renal:~* Creatinine no greater than 2 times normal~Pulmonary:~* No chronic lung disease (unless DLCO at least 60%)~Neurological:~* Neurologic function score no greater than 3~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No other malignancy within the past 5 years except carcinoma in situ of the cervix or nonmelanoma skin cancer~* No active infection~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy to the head or neck (unless brain is clearly excluded, such as radiotherapy for localized vocal cord cancer)~Surgery:~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Observation (Type: NO_INTERVENTION): Observation only.
- Radiation therapy (Type: EXPERIMENTAL): Radiation therapy only.
- Radiation plus PCV chemotherapy (Type: EXPERIMENTAL): Radiation and Procarbazine/CCNU/Vincristine (PCV) chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ProQuad Dose Selection Study (V221-011)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* In good health~* Negative clinical history of measles, mumps, rubella, varicella, and zoster~Exclusion Criteria:~* Previous receipt of measles, mumps, rubella and/or varicella vaccine either alone or in combination~* Any immune impairment or deficiency~* Exposure to measles, mumps, rubella, varicella, or zoster in the 4 weeks prior to vaccination~* Vaccination with an inactive vaccine with in the past 14 days~* Vaccination with a live vaccine within the past 30 days~* Immune globulin or any blood product administered in the past 3 months

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 23 Months
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): ProQuad (low dose)
- 2 (Type: EXPERIMENTAL): ProQuad (middle dose)
- 3 (Type: EXPERIMENTAL): ProQuad (high dose)
- 4 (Type: ACTIVE_COMPARATOR): M-M-R II + PUVV

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete